Tips to avoid patent pitfalls as market for RNAi-derived therapeutics grows

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Tips to avoid patent pitfalls as market for RNAi-derived therapeutics grows

Sponsored by

Logo 22.07.22.png
Patented Patent Copyright Law Business technology concept.

Anne Marie Clark, senior patent searcher at CAS, looks at ways to protect and commercialise the promise of RNAi

The value and complexity of the patent landscape around RNA interference (RNAi) is increasing, creating special challenges for patent searches to protect IP and maximise its value.

RNAi is claimed in a variety of ways within patents. Standard terminology is not always used, and chemical modifications can be described a variety of ways. These inconsistencies mean that there is no single search strategy that can be used to efficiently and comprehensively retrieve this information from different data sources.

Read an in-depth discussion of relevant challenges and search techniques for RNAi in this resource from CAS

Click here to access CAS’s content hub on Managing IP

more from across site and SHARED ros bottom lb

More from across our site

US corporates are using the UPC, but much of that work still flows to European boutiques. Last week’s merger, as well as others, could alter that dynamic
Publicly listed Australian group IPH delivered on its promise to profoundly shake up the Canadian market. Four years on, rivals have had time to adapt
IP practitioners debate whether new guidelines will make it more difficult to challenge a patent
Varuni Paranavitane says she is excited to bring ‘rounded expertise’ to the firm, which will have a solicitor in its ranks for the first time
Lawyers adapting to AI-driven recommendations are being pushed to demonstrate expertise publicly rather than simply relying on a polished website
Mid-market businesses looking to establish an online presence need ‘holistic’ brand protection services at an accessible cost, according to partners
Our latest update also includes the latest case filing statistics, and an update on how a transatlantic merger could be a UPC opportunity for the US half of the partnership
New partners, from biotech company Leyden Labs and Novartis, take the total number of partner hires to 12 since the firm took on external investment in late 2024
Labelled the ‘largest law firm merger in history’, the new outfit could also spell an opportunity for US clients to capitalise on Hogan Lovells' UPC expertise
Andy Lee and Amy Brooks of Brandsmiths explain how the firm secured a win for Peppa Pig over rival children’s character Wolfoo, in a case that centred on copied audio clips
Gift this article